Holen Sie sich die Stockscreener-App
42.67
0.49%
-0.21
Schlusskurs vom Vortag:
$42.88
Offen:
$42.7
24-Stunden-Volumen:
3.69M
Relative Volume:
1.24
Marktkapitalisierung:
$11.64B
Einnahmen:
$2.17B
Nettoeinkommen (Verlust:
$521.27M
KGV:
24.11
EPS:
1.77
Netto-Cashflow:
$633.79M
1W Leistung:
-0.97%
1M Leistung:
+7.75%
6M Leistung:
+21.02%
1J Leistung:
+94.57%
1-Tages-Spanne:
$42.23
$43.53
1-Wochen-Bereich:
$42.21
$43.83
52-Wochen-Spanne:
$21.36
$48.85
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Vergleichen Sie EXEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
42.67 | 11.75B | 2.17B | 521.27M | 633.79M | 1.77 |
|
ONC
Beone Medicines Ltd Adr
|
251.72 | 25.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.48 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3401 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.81 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.86 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Exelixis at 45th Annual William Blair Conference: Oncology Ambitions - Investing.com Australia
Transcript : Exelixis, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10 - marketscreener.com
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Growth in the Biotech Space with Robust Revenue Momentum - DirectorsTalk Interviews
2 Top Stocks to Buy With Less Than $100 - The Globe and Mail
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Transcript : Exelixis, Inc. Presents at TD Cowen's 6th Annual Oncology Innovation Summit, May-27-2025 02 - marketscreener.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Decreases Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort - MSN
Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress By Investing.com - Investing.com South Africa
Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress - Investing.com Australia
Deutsche Bank AG Has $1.54 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Insider Sell: Tomas Heyman Sells Shares of Exelixis Inc (EXEL) - GuruFocus
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) - Yahoo Finance
Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy? - Yahoo Finance
Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Solid Earnings Reflect Exelixis' (NASDAQ:EXEL) Strength As A Business - Yahoo Finance
Product Performance, Big Money Lift Exelixis - Yahoo Finance
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 - BioSpace
Exelixis reports promising kidney cancer trial results - Investing.com Australia
Exelixis EVP Haley Patrick J. sells $1.5 million in stock By Investing.com - Investing.com Nigeria
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-0 - GuruFocus
Exelixis EVP Haley Patrick J. sells $1.5 million in stock - Investing.com
Exelixis Executives Engage in Significant Stock Transactions - TradingView
Exelixis reports promising kidney cancer trial results By Investing.com - Investing.com India
Exelixis (EXEL) Reports Promising Results from STELLAR-002 Renal Cancer Trial | EXEL Stock News - GuruFocus
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 | EXEL Stock N - GuruFocus
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June | EXEL Stock News - GuruFocus
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June - New Castle News
Long Term Trading Analysis for (EXEL) - news.stocktradersdaily.com
Exelixis (NasdaqGS:EXEL) Reports Robust Q1 2025 Earnings and Revenue Growth - Yahoo Finance
Exelixis, Inc.: A Strategic Buy on Positive Momentum - marketscreener.com
Transcript : Exelixis, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 10 - marketscreener.com
Exelixis (EXEL) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
CoreWeave, Super Micro Computer And Coinbase Are Among Top 11 Large-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio? - Benzinga
Citigroup Boosts Exelixis (NASDAQ:EXEL) Price Target to $56.00 - Defense World
Exelixis raises 2025 revenue guidance by $100M amid strong CABOMETYX market share gains and new NET approval - MSN
Exelixis director George Poste sells $948,957 in stock - Investing.com Australia
Exelixis director George Poste sells $948,957 in stock By Investing.com - Investing.com UK
Exelixis Stock Price, Quotes and Forecasts - Benzinga
Exelixis (NASDAQ:EXEL) Stock Price Up 5.7% After Analyst Upgrade - Defense World
Exelixis Q1 2025 Earnings Call Highlights Growth - TipRanks
Guggenheim Raises Price Target for Exelixis (EXEL) Amid Strong R - GuruFocus
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line - MSN
Demystifying Exelixis: Insights From 8 Analyst Reviews - Benzinga
Exelixis (EXEL) Target Price Raised by Citigroup Analyst | EXEL Stock News - GuruFocus
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):